Piramal Pharma to invest USD 90M in expansion of two US sites

Published On 2025-05-13 05:58 GMT   |   Update On 2025-05-13 05:58 GMT

MumbaiPiramal Pharma Limited, a global pharmaceuticals and wellness company, in conjunction with the 2025 Select USA Investment Summit, has committed to a $90M investment plan towards expanding two of the Company’s US facilities.

These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply. Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market.

Advertisement

Piramal Pharma’s Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site’s expansion—which includes 24,000 square feet of manufacturing space and a new laboratory—adds commercial-scale manufacturing. Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027.

Piramal Pharma’s Riverview, Michigan site, develops and manufactures active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs). Here, the company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers. These high potency APIs are used in the development of antibody-drug conjugates (ADCs) and other bioconjugate drugs. The new payloadlinker suite is expected to be operational before the end of 2025. These site expansions are expected to generate greater opportunities for integrated ADC projects. Working synergistically, they will play a vital role in Piramal Pharma’s integrated ADC development and manufacturing program, branded ADCelerate. With development and commercial-scale capabilities in mABs, payload-linkers, conjugations, and fill/finish, ADCelerate speeds timelines, enabling project initiation to GMP drug product in just 12 months with uncompromised quality.

“Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities,” said Peter DeYoung, Chief Executive Officer, Global Pharma. “The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting.”
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News